Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Ethiopia is experiencing steady growth in recent years.
Customer preferences: The demand for immunosuppressants in Ethiopia is driven by a growing number of patients with autoimmune diseases and transplant recipients. Patients with autoimmune diseases require immunosuppressants to control their symptoms and prevent further damage to their organs. Meanwhile, transplant recipients need immunosuppressants to prevent their immune system from rejecting the transplanted organ. The preference for immunosuppressants over other treatment options is due to their effectiveness in managing these conditions.
Trends in the market: The immunosuppressants market in Ethiopia is expected to continue growing due to the increasing prevalence of autoimmune diseases and organ transplantation. The market is also driven by the availability of generic immunosuppressants, which are more affordable than branded drugs. However, the market is facing challenges such as a lack of awareness among patients and healthcare providers about the benefits of immunosuppressants and the availability of cheaper alternatives.
Local special circumstances: Ethiopia has a low-income population, which limits the affordability of expensive immunosuppressants. This has led to the development of local pharmaceutical companies that produce generic immunosuppressants at a lower cost. However, the quality of these drugs is often questionable, and patients may not receive the same level of care as they would in developed countries. Additionally, the lack of healthcare infrastructure and trained healthcare professionals in rural areas limits access to immunosuppressants for patients living in those areas.
Underlying macroeconomic factors: The Ethiopian economy is growing, but it is still one of the poorest in the world. This limits the government's ability to invest in healthcare infrastructure and provide universal healthcare coverage. The lack of healthcare infrastructure and trained healthcare professionals limits access to immunosuppressants for patients living in rural areas. The government is working to improve healthcare access and quality, but progress has been slow. Furthermore, the COVID-19 pandemic has disrupted the supply chain of immunosuppressants, leading to shortages and price increases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
